Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of PSB205 in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03986606
Recruitment Status : Not yet recruiting
First Posted : June 14, 2019
Last Update Posted : June 14, 2019
Sponsor:
Collaborator:
Pharmaceutical Research Associates
Information provided by (Responsible Party):
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Brief Summary:
This is an open-label, multicenter, Phase 1, ascending dose escalation study of PSB205 in subjects with advanced solid tumors. The study will be conducted in 2 parts. Part 1 of the study will be a dose escalation evaluation to determine the maximum tolerated dose (MTD) and to establish a recommended Phase 2 dose (RP2D) of PSB205. This study purpose is to describe the safety and tolerability, to assess Pharmacokinetics (PK) and immunogenicity, and to preliminarily assess the anti-tumor activity of PSB205 in subjects with solid tumors. Part 2 of the study will further evaluate the RP2D in 3 distinct tumor cohorts of approximately 12 subjects each.

Condition or disease Intervention/treatment Phase
Neoplasm Malignant Biological: PSB205 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients With Relapsed/Refractory Solid Tumors
Estimated Study Start Date : June 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : July 2021

Arm Intervention/treatment
Experimental: Open-label Dose Escalation and Expansion Study of PSB205

Part 1 (Dose escalation): PSB205 will be administered in sequential cohorts of 3 to 6 subjects each receiving 1 of 5 doses of PSB205 on day 1 of every 21-day cycle (3 weeks) via IV infusion using a standard 3+3 dose escalation design. Dose escalation will continue until an MTD is reached.

Part 2 (Dose Expansion): The clinical anti-tumor effects of PSB205 will be tested at the recommended Phase 2 dose (RP2D) determined during the dose-escalation phase in subjects from three different solid tumor cohorts.

Biological: PSB205
PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.




Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: 42 days ]
    Safety and tolerability, as defined by the rate of treatment-related adverse events as assessed by NCI CTCAE v5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged 18 years or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Inclusion of subjects with an ECOG performance status of 2 should be discussed and is at the discretion of the sponsor's medical monitor and the investigator.
  • Life expectancy of ≥3 months.
  • Female subjects who are not pregnant or breastfeeding, 1 year postmenopausal, or surgically sterile and males even if surgically sterilized that Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject.
  • Suitable venous access for the study-required blood sampling, including PK and Pharmacodynamic sampling.

    1. To be enrolled in Part 1 (Dose escalation), subjects must have:

      1. Histologically confirmed diagnosis of advanced solid tumor and preferably radiographically or clinically measurable disease. Subjects with non-measurable, evaluable disease are permitted
      2. One or more prior lines of therapy . No curative options and progressed on or following standard of care therapy (SOC).
    2. To be enrolled in Part 2 (Dose expansion), subjects must have:

      1. Histologically confirmed diagnosis of advanced solid tumor of the following types, and radiographically or clinically measurable disease, one or more prior lines of therapy, no curative options and progressed on or following SOC.
      2. Squamous cell carcinomas- squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of the head and neck (HNSCC)
      3. Locally advanced or metastatic gastric or gastroesophageal carcinoma
      4. Advanced or metastatic renal cell Carcinoma (clear cell, papillary, other)
      5. MSI-high colon carcinoma
      6. Small cell lung cancer
      7. Advanced urothelial cancer
      8. Metastatic melanoma I. Advanced soft-tissue or bone sarcoma

Exclusion Criteria:

  1. Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
  2. Grade 3 or Grade 4 irAEs related to prior cancer immunotherapy.
  3. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression. Subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of study drug are permitted to enroll.
  4. Hypertension unable to be controlled to ≤Grade 2 with medication.
  5. Any condition requiring systemic treatment with corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before first dose of study drug. Corticosteroids for topical use, nasal spray, and inhaled steroids are allowed. Systemic corticosteroids for prophylaxis of contrast allergy are permitted.
  6. Prior treatment with a CTLA-4 inhibitor in combination with a PD-1 or PD-L1 inhibitor.
  7. Systemic anti-cancer treatment (including investigational agents). This includes radiotherapy <2 weeks before the first dose of study drug, ≤4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T cell engaging agents; (≤8 weeks for cell-based therapy or anti-tumor vaccine) or have not recovered from acute toxic effects from prior chemotherapy and radiotherapy.
  8. Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
  9. Systemic infection requiring IV antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
  10. Subjects with a history of organ transplant.
  11. Hepatitis B surface antigen-positive or known or suspected active hepatitis C infection.
  12. Known human immunodeficiency virus (HIV) positive.
  13. Subjects with any of the following cardiovascular conditions are excluded:

    1. Acute myocardial infarction within 6 months before first dose of study drug.
    2. Current or history of New York Heart Association Class III or IV heart failure.
    3. Evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  14. Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  15. Subject has a history of alcoholism or drug abuse within the past 6 months.
  16. Vaccinations within 4 weeks of first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03986606


Contacts
Layout table for location contacts
Contact: Tiffinnie Paulson 1-913-574-6075 PaulsonTiffinnie@prahs.com
Contact: William C Fanslow, Ph.D 1-425-398-2323 ext 1006 bill@soundbiologics.com

Sponsors and Collaborators
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Pharmaceutical Research Associates

Layout table for additonal information
Responsible Party: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
ClinicalTrials.gov Identifier: NCT03986606     History of Changes
Other Study ID Numbers: PSB205-001
First Posted: June 14, 2019    Key Record Dates
Last Update Posted: June 14, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Qilu Puget Sound Biotherapeutics (dba Sound Biologics):
neoplasm
checkpoint inhibitor
combination
immunotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms